Neumora Therapeutics Inc. (NASDAQ: NMRA) on Monday, soared 9.08% from the previous trading day, before settling in for the closing price of $10.46. Within the past 52 weeks, NMRA’s price has moved between $8.33 and $21.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 58.92%. With a float of $54.90 million, this company’s outstanding shares have now reached $158.83 million.
Considering the fact that the conglomerate employs 124 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Neumora Therapeutics Inc. (NMRA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Neumora Therapeutics Inc. is 65.70%, while institutional ownership is 27.62%. The most recent insider transaction that took place on Aug 27 ’24, was worth 178,806. In this transaction Chief Financial Officer of this company sold 15,693 shares at a rate of $11.39, taking the stock ownership to the 138,965 shares. Before that another transaction happened on Aug 26 ’24, when Company’s Chief Financial Officer sold 31,642 for $11.78, making the entire transaction worth $372,588. This insider now owns 154,658 shares in total.
Neumora Therapeutics Inc. (NMRA) Earnings and Forecasts
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -1.14 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.36) by -0.78. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 58.92% per share during the next fiscal year.
Neumora Therapeutics Inc. (NASDAQ: NMRA) Trading Performance Indicators
Neumora Therapeutics Inc. (NMRA) is currently performing well based on its current performance indicators. A quick ratio of 17.22 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.74, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.60 in one year’s time.
Technical Analysis of Neumora Therapeutics Inc. (NMRA)
Compared to the last year’s volume of 0.6 million, its volume of 0.43 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 29.98%. Additionally, its Average True Range was 0.67.
During the past 100 days, Neumora Therapeutics Inc.’s (NMRA) raw stochastic average was set at 60.62%, which indicates a significant increase from 54.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.10% in the past 14 days, which was higher than the 56.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.42, while its 200-day Moving Average is $12.85. Nevertheless, the first resistance level for the watch stands at $11.75 in the near term. At $12.10, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.73. If the price goes on to break the first support level at $10.77, it is likely to go to the next support level at $10.14. Should the price break the second support level, the third support level stands at $9.79.
Neumora Therapeutics Inc. (NASDAQ: NMRA) Key Stats
Market capitalization of the company is 1.83 billion based on 159,524K outstanding shares. Right now, sales total 0 K and income totals -235,930 K. The company made 0 K in profit during its latest quarter, and -58,700 K in sales during its previous quarter.
